Exercise to Improve Heart and Metabolic Health After Childbirth in Women at High Risk for Preeclampsia
NCT07921173, Not applicable, Recruiting, Chinese University of Hong Kong
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Exercise to Improve Heart and Metabolic Health After Childbirth in Women at High Risk for Preeclampsia | ClinicalTrials.gov |
| NCT number | NCT07921173 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 40 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Chinese University of Hong Kong | ClinicalTrials.gov |
| Conditions | Postpartum Exercise, Cardiometabolic Health, High Risk for Preeclampsia, Randomized Controlled Trial | ClinicalTrials.gov |
| Interventions | Postpartum Exercise Program | ClinicalTrials.gov |
| First posted | 2026-11-06 | ClinicalTrials.gov |
| Last updated | 2026-11-06 | ClinicalTrials.gov |
Registered outcomes 32
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Systolic Blood Pressure | Before and after the 12-week exercise intervention | Systolic blood pressure will be measured in mmHg. Change from baseline to the end of the 12-week intervention will be assessed. | ClinicalTrials.gov |
| Primary | Change in Diastolic Blood Pressure | Baseline and 12 weeks | Diastolic blood pressure will be measured in mmHg using a validated automated device. Change from baseline to the post-intervention assessment will be assessed. | ClinicalTrials.gov |
| Secondary | Change in Triglyceride Levels | Baseline and 12 weeks | Serum triglyceride levels will be determined using standard laboratory techniques. Changes in levels will be assessed. | ClinicalTrials.gov |
| Secondary | Change in Total Cholesterol Levels | Baseline and 12 weeks | Serum total cholesterol levels will be determined using standard laboratory techniques. Changes in levels will be assessed. | ClinicalTrials.gov |
| Secondary | Change in High-Density Lipoprotein Cholesterol Levels | Baseline and 12 weeks | Serum high-density lipoprotein cholesterol levels will be determined using standard laboratory techniques. Changes in levels will be assessed. | ClinicalTrials.gov |
| Secondary | Change in Low-Density Lipoprotein Cholesterol Levels | Baseline and 12 weeks | Serum low-density lipoprotein cholesterol levels will be determined using standard laboratory techniques. Changes in levels will be assessed. | ClinicalTrials.gov |
| Secondary | Change in Apolipoprotein A-I Levels | Baseline and 12 weeks | Apolipoprotein A-I levels will be measured using ELISA. Changes in levels will be assessed. | ClinicalTrials.gov |
| Secondary | Change in Apolipoprotein A-II Levels | Baseline and 12 weeks | Apolipoprotein A-II levels will be measured using ELISA. Changes in levels will be assessed. | ClinicalTrials.gov |
| Secondary | Change in Apolipoprotein B Levels | Baseline and 12 weeks | Apolipoprotein B levels will be measured using ELISA. Changes in levels will be assessed. | ClinicalTrials.gov |
| Secondary | Change in Fasting Glucose Levels | Baseline and 12 weeks | Fasting glucose levels will be determined using standard laboratory tests. Changes in levels will be assessed. | ClinicalTrials.gov |
| Secondary | Change in Glycated Hemoglobin (HbA1c) | Baseline and 12 weeks | HbA1c will be determined using standard laboratory tests. Changes in levels will be assessed. | ClinicalTrials.gov |
| Secondary | Change in Fasting Insulin Levels | Baseline and 12 weeks | Fasting insulin levels will be measured using ELISA. Changes in levels will be assessed. | ClinicalTrials.gov |
| Secondary | Change in C-Peptide Levels | Baseline and 12 weeks | C-peptide levels will be measured using ELISA. Changes in levels will be assessed. | ClinicalTrials.gov |
| Secondary | Change in Adiponectin Levels | Baseline and 12 weeks | Adiponectin levels will be measured using ELISA. Changes in levels will be assessed. | ClinicalTrials.gov |
| Secondary | Change in Leptin Levels | Baseline and 12 weeks | Leptin levels will be measured using ELISA. Changes in levels will be assessed. | ClinicalTrials.gov |
| Secondary | Change in High-Sensitivity C-Reactive Protein Levels | Baseline and 12 weeks | High-sensitivity C-reactive protein levels will be measured using ELISA. Changes in levels will be assessed. | ClinicalTrials.gov |
| Secondary | Change in Tumor Necrosis Factor-Alpha Levels | Baseline and 12 weeks | Tumor necrosis factor-alpha levels will be measured using ELISA. Changes in levels will be assessed. | ClinicalTrials.gov |
| Secondary | Change in Interleukin-6 Levels | Baseline and 12 weeks | Interleukin-6 Levels Interleukin-6 levels will be measured using ELISA. Changes in levels will be assessed. | ClinicalTrials.gov |
| Secondary | Change in Fibrinogen Levels | Baseline and 12 weeks | Blood fibrinogen levels will be measured using a commercial ELISA kit. Changes in levels will be assessed. | ClinicalTrials.gov |
| Secondary | Change in Endothelin-1 Levels | Baseline and 12 weeks | Endothelin-1 Levels Endothelin-1 levels will be measured using a commercial ELISA kit. Changes in levels will be assessed. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)